Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
8Customers
1Debt Items
14Related Chains
Source-Backed Evidence Depth
Biomerica, Inc. (BMRA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
3Distinct source URLs
9High confidence
0.815Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Biomerica, Inc. Suppliers
Ticker
Name
Confidence
Evidence
DIAGNOSIS-S-A
DIAGNOSIS-S-A
92%
the Company agreed to sell to the Buyers 78,750 shares owned by the Company (the “Shares”) of Diagnosis S.A., a medical products producer and distributor headquartered in Białystok, Poland
ASIA
ASIA
90%
For the three months ended February 28, 2026, we had two key vendors that accounted for 36 % of purchases of raw materials.
VENDOR
VENDOR
90%
For the fiscal year ended May 31, 2024, the Company had one vendor which accounted for 16 % of the purchases of raw materials.
Biomerica, Inc. Customers
Ticker
Name
Confidence
Evidence
ASIA
ASIA
90%
For the nine months ended February 28, 2026, we had one key customer located in Asia that accounted for 36 % of net consolidated sales.
DISTRIBUTOR
DISTRIBUTOR
90%
For the fiscal years ended May 31, 2024, and 2023, the Company had one distributor each year that accounted for 33 % and 35 % of our net sales, respectively.
MIDDLE-EAST
MIDDLE-EAST
85%
For the three months ended February 28, 2026, we had three key customers located in Asia, the Middle East, and the United States, which accounted for 50 % of net consolidated sales.
ZACKARY-IRANI
ZACKARY-IRANI
85%
The Buyers are affiliated with Zackary Irani, the Company’s Chief Executive Officer
EUROPE
EUROPE
80%
As of those dates, we had three and four key customers, respectively, located in Asia, the Middle East, the United States, and Europe, which accounted for 51 % and 69 % of gross accounts receivable, …
some products are cleared for sale in the United States by the FDA. NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES PRINCIPLES OF CONSOLIDATION The consolidated financial statements for the years …
COST-METHOD-HOLDINGS
COST-METHOD-HOLDINGS
62%
purchased technology use rights, and patents are based on their individual useful lives which average around 15 years. Amortization amounted to approximately $ 18,000 for the years ended May 31, 2024…
Biomerica, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BMRA-DEBT
Debt stack $193,000
90%
Market cache reports total debt of $193,000.
Biomerica, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Biomerica, Inc..
Biomerica, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Biomerica, Inc..
